Daiichi Sankyo Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: Japan
Identifier: TKS:4568
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 86 out of 850
Universe
Global Universe 4348 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| GSK Plc |
15
Low
|
16 out of 850 |
| Merck KGaA |
16.9
Low
|
41 out of 850 |
| Daiichi Sankyo Co., Ltd. |
19.9
Low
|
86 out of 850 |
| Takeda Pharmaceutical Co., Ltd. |
21.3
Medium
|
108 out of 850 |
| Sun Pharmaceutical Industries Ltd. |
31.5
High
|
551 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for Daiichi Sankyo Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Daiichi Sankyo Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
